Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7300
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    82.60
    -0.21 (-0.25%)
     
  • Bitcoin CAD

    87,818.53
    -3,680.79 (-4.02%)
     
  • CMC Crypto 200

    1,392.19
    -31.91 (-2.24%)
     
  • GOLD FUTURES

    2,331.80
    -6.60 (-0.28%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,467.50
    -197.00 (-1.12%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    37,893.40
    -566.68 (-1.47%)
     
  • CAD/EUR

    0.6815
    -0.0004 (-0.06%)
     

UPDATE 3-Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 bln deal

(Adds quotes, background)

By Niket Nishant and Krystal Hu

May 11 (Reuters) - Ginkgo said on Tuesday it was planning to go public through a merger with a blank-check vehicle backed by former Hollywood executives Harry Sloan and Jeff Sagansky, in one of the biggest such deals that values the biotech company at $17.5 billion.

The merger is expected to fetch $2.5 billion in proceeds for the combined entity, the companies said, including $775 million from institutional investors such as Baillie Gifford, Putnam Investments and accounts advised by ARK Investment Management. Reuters reported on the company's plans last month.

ADVERTISEMENT

Founded by a team of scientists at Massachusetts Institute of Technology in 2009, Ginkgo makes genetic engineering tools for industries across agriculture, pharmaceuticals and cosmetics. It currently runs 70 programs with customers including Moderna and Cargill.

The deal gives Ginkgo a pre-money equity valuation of $15 billion. The company was valued at $4.86 billion during a private raise in May 2020, according to PitchBook data. It's also backed by Bill Gates' private investment firm Cascade Investment.

"Raising capital allows us to build bigger facilities and add support services that make it easier for people to develop on our platform. The public market is a good source of that," Ginkgo co-founder and Chief Executive Officer Jason Kelly said.

Boston-based Ginkgo expects $150 million in revenue in 2021, a 96% jump from a year earlier. It received a $1.1 billion loan from the U.S. government in November for COVID-19 testing and production of raw materials for therapies that may help address future pandemics.

Special purpose acquisition vehicles, or SPACs, are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.

Soaring Eagle is also backed by SPAC veteran Eli Baker, who is its chief financial officer.

Sloan, a former CEO of Metro Goldwyn Mayer, and Sagansky took gaming firms DraftKings Inc and Skillz Inc public last year through similar deals.

The Ginkgo deal signals a rebound in activity after Wall Street appetite for new SPACs showed signs of waning during a period that saw regulators weigh measures to rein in the pace of dealmaking through blank-check companies.

Soaring Eagle raised $1.7 billion through an IPO in February. (Reporting by Niket Nishant and Noor Zainab Hussain in Bengaluru, Krystal Hu in New York; Editing by Shounak Dasgupta and Anil D'Silva)